Amicus Therapeutics’ (FOLD) Overweight Rating Reaffirmed at J P Morgan Chase & Co
Amicus Therapeutics, Inc. (NASDAQ:FOLD)‘s stock had its “overweight” rating reissued by analysts at J P Morgan Chase & Co in a research report issued to clients and investors on Wednesday.
FOLD has been the topic of a number of other research reports. Zacks Investment Research raised Amicus Therapeutics from a “sell” rating to a “hold” rating in a report on Wednesday, July 19th. BidaskClub lowered shares of Amicus Therapeutics from a “buy” rating to a “hold” rating in a research report on Friday, August 11th. Chardan Capital reissued a “buy” rating and issued a $16.50 price objective (down from $17.50) on shares of Amicus Therapeutics in a research note on Wednesday, September 13th. Robert W. Baird upped their price objective on shares of Amicus Therapeutics from $12.00 to $15.00 and gave the stock an “outperform” rating in a research report on Wednesday, July 12th. Finally, Cowen and Company restated an “outperform” rating and issued a $18.00 target price (up previously from $16.00) on shares of Amicus Therapeutics in a research note on Thursday, September 14th. Two analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. Amicus Therapeutics presently has a consensus rating of “Buy” and an average price target of $17.58.
Amicus Therapeutics (NASDAQ:FOLD) traded up 9.21% during trading on Wednesday, hitting $16.24. 10,581,939 shares of the company traded hands. The company’s 50-day moving average is $13.82 and its 200 day moving average is $10.45. The firm’s market cap is $2.67 billion. Amicus Therapeutics has a 52-week low of $4.41 and a 52-week high of $16.60.
Amicus Therapeutics (NASDAQ:FOLD) last posted its quarterly earnings data on Monday, August 7th. The biopharmaceutical company reported ($0.34) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.37) by $0.03. Amicus Therapeutics had a negative return on equity of 61.25% and a negative net margin of 1,279.88%. The firm had revenue of $7.16 million during the quarter, compared to the consensus estimate of $6.96 million. During the same period in the prior year, the business earned ($0.40) EPS. On average, equities analysts anticipate that Amicus Therapeutics will post ($1.31) earnings per share for the current year.
In related news, major shareholder Life Sciences Maste Perceptive purchased 1,500,000 shares of Amicus Therapeutics stock in a transaction dated Thursday, July 13th. The stock was bought at an average cost of $12.25 per share, for a total transaction of $18,375,000.00. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Company insiders own 3.40% of the company’s stock.
Hedge funds have recently bought and sold shares of the stock. Teacher Retirement System of Texas raised its holdings in shares of Amicus Therapeutics by 1.7% in the second quarter. Teacher Retirement System of Texas now owns 10,243 shares of the biopharmaceutical company’s stock worth $103,000 after acquiring an additional 169 shares during the last quarter. DORCHESTER WEALTH MANAGEMENT Co acquired a new stake in shares of Amicus Therapeutics during the second quarter valued at $111,000. Tudor Investment Corp ET AL acquired a new stake in shares of Amicus Therapeutics during the second quarter valued at $124,000. Aperio Group LLC boosted its stake in shares of Amicus Therapeutics by 13.5% during the second quarter. Aperio Group LLC now owns 13,986 shares of the biopharmaceutical company’s stock valued at $141,000 after acquiring an additional 1,663 shares during the last quarter. Finally, Zacks Investment Management acquired a new stake in shares of Amicus Therapeutics during the second quarter valued at $145,000.
Amicus Therapeutics Company Profile
Amicus Therapeutics, Inc is a biotechnology company. The Company is engaged in the discovery, development and commercialization of a set of treatments for patients living with devastating rare and orphan diseases. Its lead product, migalastat HCl is a small molecule that can be used as a monotherapy and in combination with enzyme replacement therapy (ERT) for Fabry disease.
Receive News & Stock Ratings for Amicus Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amicus Therapeutics Inc. and related stocks with our FREE daily email newsletter.